Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.20.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 4,073 $ 5,223
Receivables 423 993
Inventory 1,073 998
Prepaid expenses and other current assets 1,080 1,094
Total current assets 6,649 8,308
Property and equipment, net 1,161 817
Operating lease right-of-use asset 208 397
Total assets 8,018 9,522
Current liabilities:    
Accounts payable 1,750 1,401
Accrued clinical trials expenses 829 309
Accrued sales allowances 119 809
Other accrued liabilities 875 809
Operating lease liability, current 222 272
Current portion of long-term debt 2,082 0
Total current liabilities 5,877 3,600
Operating lease liability, non-current 0 150
Long-term debt 3,038 4,019
Warrant liability 0 320
Total liabilities 8,915 8,089
Stockholders' equity (deficit):    
Common stock, at amounts paid-in 117 57
Additional paid-in capital 363,180 350,413
Accumulated deficit (364,194) (349,037)
Total stockholders' equity (deficit) (897) 1,433
Total liabilities and stockholders' equity (deficit) $ 8,018 $ 9,522